FDAMA Off-Label Provisions Were Premised On "Distrust" - Sen. Frist
One of the primary authors of the FDA Modernization Act off-label information dissemination compromise has declared his support for a federal court decision striking down the provisions.
You may also be interested in...
The ruling overturning FDA's regulation of off-label reprint dissemination offers no viable alternatives for encouraging companies to file supplemental new drug applications, FDA's appeal of Washington Legal Foundation v. Henney argues.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials